These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. [Study of humoral and cellular immunity in the course of ovarian carcinoma]. Laghi V; Carella G; Burrai I; Sacco F; Margariti PA; Villani L; Benedetti Panici P Minerva Ginecol; 1979 Oct; 31(10):737-46. PubMed ID: 317512 [No Abstract] [Full Text] [Related]
46. CA 125 in the follow-up of patients with ovarian cancer. Koelbl H; Schieder K; Neunteufel W; Bieglmayer C Eur J Obstet Gynecol Reprod Biol; 1988 Apr; 27(4):335-42. PubMed ID: 3164284 [TBL] [Abstract][Full Text] [Related]
47. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors]. Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801 [TBL] [Abstract][Full Text] [Related]
48. CA 125 surveillance and second-look laparotomy in ovarian carcinoma. Atack DB; Nisker JA; Allen HH; Tustanoff ER; Levin L Am J Obstet Gynecol; 1986 Feb; 154(2):287-9. PubMed ID: 3456202 [TBL] [Abstract][Full Text] [Related]
49. Immunologic studies of human serous cystadenocarcinoma of ovary. Demonstration of tumor-associated antigens. Bhattacharya M; Barlow JJ Cancer; 1973 Mar; 31(3):588-95. PubMed ID: 4632680 [No Abstract] [Full Text] [Related]
50. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer]. Paulick R; Kaesemann H; Caffier H Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919 [TBL] [Abstract][Full Text] [Related]
51. CA 125 and TPA as markers in ovarian carcinoma. Rodenburg CJ; De Maaker GA; Trimbos JB; Moolenaar AJ; Van Oosterom AT Neth J Med; 1985; 28(12):536-40. PubMed ID: 2418375 [No Abstract] [Full Text] [Related]
52. [Polysaccharide complex of human ovarian cancer studied by the microprecipitation reaction]. Gorodilova VV; Ul'chenko VM Vopr Onkol; 1980; 26(11):62-5. PubMed ID: 7456427 [TBL] [Abstract][Full Text] [Related]
53. Heterophile antigens in serous cystadenocarcinoma of the human ovary. Kamada M; Mori T; Sakamoto Y; Daitoh T; Furumoto H; Irahara M; Aono T; Mori T Asia Oceania J Obstet Gynaecol; 1992 Dec; 18(4):387-95. PubMed ID: 1283511 [TBL] [Abstract][Full Text] [Related]
54. Time-resolved immunofluorometric assay for the ovarian carcinoma-associated antigenic determinant CA 125 in serum. Boerman OC; Thomas CM; Segers MF; Kenemans P; Lövgren T; Zurawski VR; Haisma HJ; Poels LG Clin Chem; 1987 Dec; 33(12):2191-4. PubMed ID: 2446805 [TBL] [Abstract][Full Text] [Related]
55. Tumor-associated antigen(s) from granulosa cell carcinomas of the ovary. Bhattacharya M; Barlow JJ; Chu TM; Piver MS Cancer Res; 1974 Apr; 34(4):818-22. PubMed ID: 4205513 [No Abstract] [Full Text] [Related]
56. Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. Imai S; Kiyozuka Y; Maeda H; Noda T; Hosick HL Oncology; 1990; 47(2):177-84. PubMed ID: 2314830 [TBL] [Abstract][Full Text] [Related]
57. CA 125 in ovarian cancer. van der Burg ME; Lammes FB; Verweij J Neth J Med; 1992 Feb; 40(1-2):36-51. PubMed ID: 1579185 [TBL] [Abstract][Full Text] [Related]
58. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Vergote IB; Børmer OP; Abeler VM Am J Obstet Gynecol; 1987 Jul; 157(1):88-92. PubMed ID: 2440307 [TBL] [Abstract][Full Text] [Related]
59. Clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer--a study on 674 patients. Takahashi K; Shibukawa T; Moriyama M; Shirai T; Kijima S; Iwanari O; Matsunaga I; Kitao M Jpn J Surg; 1986 Sep; 16(5):305-10. PubMed ID: 3467109 [TBL] [Abstract][Full Text] [Related]
60. [Distribution and diagnostic role of COTA in mucinous ovarian tumors]. Shi ZL Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):191-2. PubMed ID: 2612330 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]